C K Lam1, K Fluegge2, M Macaraig3, J Burzynski3. 1. Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, Queens, NY, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA. 2. Policy, Planning and Strategic Data Use, Office of the First Deputy Commissioner, New York City Department of Health and Mental Hygiene, Queens, NY, Institute of Health and Environmental Research, Cleveland, OH, USA. 3. Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, Queens, NY.
Abstract
OBJECTIVE: To calculate the per-session and annual direct program costs to implement directly observed therapy (DOT) for tuberculosis treatment and to conduct a cost attribution analysis under varying proportions of DOT utilization for four DOT types. DESIGN: Program data covering the study period from September 2014 to August 2015 in New York City (NYC) were used to conduct a retrospective bottom-up micro-costing economic evaluation. For each DOT type, potential per-session and annual program savings were estimated as the cost averted by adopting a uniform distribution of DOT alternatives. Sensitivity analyses explored aggregate cost impacts of unequal distributions. RESULTS: There was a total of 38 035 unique DOT visits, of which 12 002 (32%) were clinic-based (CDOT); 15 483 (41%) were field-based (FDOT); 7185 (19%) were live-video (LVDOT); and 3365 (9%) were recorded-video (RVDOT). The per-session direct costs (in 2016 $US) for DOT services delivered during the study period were $8.46 for CDOT; $19.83 for FDOT; $6.54 for LVDOT; and $5.35 for RVDOT. Sensitivity analyses supported the main findings. CONCLUSIONS: Significant cost savings were estimated with increased utilization of VDOT. Assuming equivalent treatment adherence, duration, completion, and adverse events across DOT types, RVDOT was the modality that most minimized cost.
OBJECTIVE: To calculate the per-session and annual direct program costs to implement directly observed therapy (DOT) for tuberculosis treatment and to conduct a cost attribution analysis under varying proportions of DOT utilization for four DOT types. DESIGN: Program data covering the study period from September 2014 to August 2015 in New York City (NYC) were used to conduct a retrospective bottom-up micro-costing economic evaluation. For each DOT type, potential per-session and annual program savings were estimated as the cost averted by adopting a uniform distribution of DOT alternatives. Sensitivity analyses explored aggregate cost impacts of unequal distributions. RESULTS: There was a total of 38 035 unique DOT visits, of which 12 002 (32%) were clinic-based (CDOT); 15 483 (41%) were field-based (FDOT); 7185 (19%) were live-video (LVDOT); and 3365 (9%) were recorded-video (RVDOT). The per-session direct costs (in 2016 $US) for DOT services delivered during the study period were $8.46 for CDOT; $19.83 for FDOT; $6.54 for LVDOT; and $5.35 for RVDOT. Sensitivity analyses supported the main findings. CONCLUSIONS: Significant cost savings were estimated with increased utilization of VDOT. Assuming equivalent treatment adherence, duration, completion, and adverse events across DOT types, RVDOT was the modality that most minimized cost.
Authors: K Krueger; D Ruby; P Cooley; B Montoya; A Exarchos; B M Djojonegoro; K Field Journal: Int J Tuberc Lung Dis Date: 2010-06 Impact factor: 2.373
Authors: Richard S Garfein; Lin Liu; Jazmine Cuevas-Mota; Kelly Collins; Fatima Muñoz; Donald G Catanzaro; Kathleen Moser; Julie Higashi; Teeb Al-Samarrai; Paula Kriner; Julie Vaishampayan; Javier Cepeda; Michelle A Bulterys; Natasha K Martin; Phillip Rios; Fredric Raab Journal: Emerg Infect Dis Date: 2018-10 Impact factor: 6.883
Authors: Marjorie Z Imperial; Payam Nahid; Patrick P J Phillips; Geraint R Davies; Katherine Fielding; Debra Hanna; David Hermann; Robert S Wallis; John L Johnson; Christian Lienhardt; Rada M Savic Journal: Nat Med Date: 2018-11-05 Impact factor: 53.440
Authors: R S Garfein; K Collins; F Muñoz; K Moser; P Cerecer-Callu; F Raab; P Rios; A Flick; M L Zúñiga; J Cuevas-Mota; K Liang; G Rangel; J L Burgos; T C Rodwell; K Patrick Journal: Int J Tuberc Lung Dis Date: 2015-09 Impact factor: 2.373
Authors: Garrett R Beeler Asay; Chee Kin Lam; Brock Stewart; Joan M Mangan; Laura Romo; Suzanne M Marks; Sapna Bamrah Morris; Caroline L Gummo; Chris E Keh; Andrew N Hill; Anila Thomas; Michelle Macaraig; Kristen St John; Teresita J Ampie; Christine Chuck; Joseph Burzynski Journal: Am J Public Health Date: 2020-09-17 Impact factor: 9.308